NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Idera Pharmaceuticals Inc (NASDAQ: IDRA)
IDRA Technical Analysis
5
As on 18th Jan 2023 IDRA SHARE Price closed @ 8.64 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.69 & Strong Buy for SHORT-TERM with Stoploss of 1.05 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IDRASHARE Price
Open | 12.75 | Change | Price | % |
High | 16.00 | 1 Day | 8.21 | 1909.30 |
Low | 8.64 | 1 Week | 7.93 | 1116.90 |
Close | 8.64 | 1 Month | 8.31 | 2518.18 |
Volume | 1126300 | 1 Year | 7.59 | 722.86 |
52 Week High 1.11 | 52 Week Low 0.23 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
OPTT | 0.70 | 40.00% |
SMCI | 42.00 | 28.68% |
NVDA | 138.63 | 0.27% |
INTC | 23.93 | -0.50% |
MARA | 25.63 | -6.53% |
LMDX | 0.02 | 0.00% |
PLUG | 2.30 | 2.68% |
SGBX | 0.68 | 41.67% |
TSLA | 357.09 | 3.46% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
IDRA Daily Charts |
IDRA Intraday Charts |
Whats New @ Bazaartrend |
IDRA Free Analysis |
|
IDRA Important Levels Intraday
RESISTANCE | 22.82 |
RESISTANCE | 18.27 |
RESISTANCE | 15.46 |
RESISTANCE | 12.65 |
SUPPORT | 4.63 |
SUPPORT | 1.82 |
SUPPORT | -0.99 |
SUPPORT | -5.54 |
IDRA Forecast December 2024
4th UP Forecast | 8.93 |
3rd UP Forecast | 8.84 |
2nd UP Forecast | 8.78 |
1st UP Forecast | 8.72 |
1st DOWN Forecast | 8.56 |
2nd DOWN Forecast | 8.5 |
3rd DOWN Forecast | 8.44 |
4th DOWN Forecast | 8.35 |
IDRA Weekly Forecast
4th UP Forecast | 8.85 |
3rd UP Forecast | 8.78 |
2nd UP Forecast | 8.74 |
1st UP Forecast | 8.70 |
1st DOWN Forecast | 8.58 |
2nd DOWN Forecast | 8.54 |
3rd DOWN Forecast | 8.50 |
4th DOWN Forecast | 8.43 |
IDRA Forecast2024
4th UP Forecast | 39.05 |
3rd UP Forecast | 29.3 |
2nd UP Forecast | 23.27 |
1st UP Forecast | 17.24 |
1st DOWN Forecast | 0.04 |
2nd DOWN Forecast | -5.99 |
3rd DOWN Forecast | -12.02 |
4th DOWN Forecast | -21.77 |
Idera Pharmaceuticals Inc ( NASDAQ USA Symbol : IDRA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IDRA Other Details
Segment | EQ | |
Market Capital | 45406976.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
IDRA Address
IDRA Latest News
IDRA Business Profile
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania. Address: 505 Eagleview Boulevard, Exton, PA, United States, 19341
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service